

K041032  
Page 1 of 2

**MAY 10 2004**      510(k) Statement

1.    **Submitter:**                      Orbus Medical Technologies, Inc  
   5363 NW 35th Ave  
   Fort Lauderdale, Florida 33309  
   Phone: (954) 730-0711  
   Fax: (954) 730-7601
2.    **Contact:**                              Jim Clossick  
   Director of Quality Assurance and Regulatory Affairs
3.    **Date Prepared:**                      3/1/04
4.    **Device Trade Name:**                LifeStent XL SDS Biliary Endoprosthesis
5.    **Device Common Name:**              Biliary stent
6.    **Device Classification:**              Biliary Catheter (78 FGE)
7.    **Predicate Devices:**                LifeStent SDS Biliary Endoprosthesis

8.    **Description:**

The LifeStent XL SDS Biliary Endoprosthesis consists of a balloon expandable stent which is provided mounted onto a percutaneous transluminal angioplasty (PTA) balloon catheter which acts as the delivery system. The stent is a permanently implanted device used to maintain patency of a major bile duct obstructed by tissue of an impinging tumor. The flexible, balloon expandable stent is made by laser cutting an open lattice design into a 316L stainless steel tube. The stent is supplied mounted onto a PTA balloon catheter, inserted percutaneously to the diseased site, and expanded by balloon inflation. The systems are available with expanded diameter of 100mm at stent lengths of 17, 27, 37mm.

9.    **Intended Use:**

The LifeStent XL SDS Biliary Endoprosthesis are intended for the palliation of malignant neoplasms in the biliary tree.

10.   **Technological Characteristics:**

Comparisons of the new and predicate devices were designed to show that the technical characteristics such as materials, performance properties, biocompatibility, method of sterilization, and packaging are identical or substantially equivalent.

K041032  
Page 2 of 2

**11. Performance Data:**

Orbus protocols ensure that the LifeStent XL SDS Biliary Endoprosthesis perform in a manner substantially equivalent to the predicate devices during *in vitro* tests such as deployment, expansion force, compression force, dimensions, corrosion susceptibility, visual appearance, balloon performance, expansion damage, and balloon tensile strength.

**12. Conclusion**

Since the LifeStent XL SDS Biliary Endoprosthesis, comprised of the Ø 8-12 mm LifeStent (K023121) and the Opti-Plast XT catheter (K941706), has the same intended use, identical material properties, similar performance properties, packaging, and sterilization methods, it may be considered substantially equivalent to the predicate devices cited in (7). These devices are a line extension to the LifeStent XL 8 and 9mm Biliary Endoprosthesis previously cleared per K040550.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 10 2004

Mr. Jim Clossick  
Director of Quality Assurance and Regulatory Affairs  
Orbus Medical Technologies  
5363 NW 35<sup>th</sup> Avenue  
Fort Lauderdale, Florida 33309

Re: K041032  
Trade/Device Name: Orbus LifeStent XL SDS Biliary Endoprosthesis  
Regulation Number: 21 CFR §876.5010  
Regulation Name: Biliary catheter and accessories  
Regulatory Class: II  
Product Code: 78 FGE  
Dated: April 19, 2004  
Received: April 21, 2004

Dear Mr. Clossick:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

Page 2 – Mr. Jim Clossick

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4616. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

  
for Donna-Bea Tillman, Ph.D.  
Acting Director  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number: K041032

Device Name: Orbus LifeStent XL SDS Biliary Endoprosthesis


FDA's Statement of the Indications For Use for device:

The Orbus LifeStent XL SDS Biliary Endoprosthesis is indicated for the palliation of malignant neoplasms in the biliary tree.

Prescription Use    
 (Per 21 CFR 801.109)

OR

Over-the-Counter Use



(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices

510(k) Number K041032